Dr. Muss on Optimizing Adjuvant Treatment for Older Breast Cancer Patients

Hyman B. Muss, MD
Published: Saturday, Feb 28, 2015

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.

Muss says the average age of breast cancer patient in the US is 61 and the majority of women who don’t survive breast cancer are 65 and older. Older breast cancer patients typically do not qualify for clinical trials due to their age or comorbidities.

Comorbidities also make it difficult to treat these patients and may even be more serious than their breast cancer. Muss says the goal of treating these patients is to understand their functional status, talk to them about their goals, and help them maintain the highest quality of life possible.

<<< View more from the 32nd Annual Miami Breast Cancer Conference

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses optimizing adjuvant treatment in older patients with breast cancer.

Muss says the average age of breast cancer patient in the US is 61 and the majority of women who don’t survive breast cancer are 65 and older. Older breast cancer patients typically do not qualify for clinical trials due to their age or comorbidities.

Comorbidities also make it difficult to treat these patients and may even be more serious than their breast cancer. Muss says the goal of treating these patients is to understand their functional status, talk to them about their goals, and help them maintain the highest quality of life possible.

<<< View more from the 32nd Annual Miami Breast Cancer Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x